Breaking News Instant updates and real-time market news.

RDUS

Radius Health

$27.41

0.71 (2.66%)

18:34
12/07/17
12/07
18:34
12/07/17
18:34

Radius Healths says elacestrant still 'shows promise' in advanced breast cancer

Radius Health provided an update on data from the Phase 1 005 clinical study of elacestrant, an oral selective estrogen receptor degrader, in patients with estrogen receptor positive breast cancer. The data were presented at a Spotlight Presentation during the 2017 San Antonio Breast Cancer Symposium. Elacestrant recently received Fast Track designation from the U.S. Food and Drug Administration. There are 40 patients that have been treated at the 400 mg dose in the elacestrant Phase I dose escalation and expansion cohorts. All study participants are heavily pretreated ER+, HER2-negative, advanced breast cancer patients that have received a median of three prior lines of systemic therapy and have evaluable advanced or metastatic disease. Of the enrolled patients, 22 patients met the RECIST measurable disease criteria at baseline and there were 6 confirmed partial responses in this group. Elacestrant was well-tolerated with the most common adverse events being low grade nausea, dyspepsia and vomiting. "It is quite encouraging to see the clinical activity with elacestrant in the heavily pretreated advanced patient population, and further therapeutic development is warranted for patients with hormone receptor positive breast cancer", commented Dr. Aditya Bardia, Director of Precision Medicine and attending physician at Center for Breast Cancer, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.

RDUS Radius Health
$27.41

0.71 (2.66%)

05/22/17
JPMS
05/22/17
NO CHANGE
Target $74
JPMS
Overweight
Amgen data a 'clear positive' for Radius Health, says JPMorgan
JPMorgan analyst Jessica Fye believes the imbalance in observed cardiovascular serious adverse events reported by Amgen (AMGN) and UCB over the weekend for Evenity is a "clear positive" for Radius Health (RDUS). The FDA will now add results from the Phase 3 ARCH study to the regulatory review, and as a result Amgen does not expect U.S. approval for Evenity in 2017, Fye tells investors in a research note. The update is a "clear positive" for Radius Health, who has Tymlos already approved with a clean clinical safety profile, the analyst contends. She continues to believe Tymlos is well positioned for a successful launch into the large market opportunity of postmenopausal women with osteoporosis at high risk of fracture. Fye has an Overweight rating on Radius with a $74 price target. The stock in premarket trading is up 13%, or $4.62, to $39.55.
05/22/17
LEER
05/22/17
NO CHANGE
Target $159
LEER
Market Perform
Leerink sees only 50/50 chance of Amgen's Evenity hitting market
After Amgen (AMGN) and UCB reported an "imbalance of positively adjudicated serious cardiovascular adverse events" in its Phase 3 study of Evenity, Leerink analyst Geoffrey Porges believes the product now has only a 50/50 probability of coming to market at all. The analyst lowered his price target for Amgen shares to $159 from $160 and keeps a Market Perform rating on the name. Radius Health (RDUS), which has a drug that would compete with Evenity, is trading up 16% to $40.58 in the premarket.
05/22/17
ADAM
05/22/17
NO CHANGE
Target $85
ADAM
Buy
CV events 'may kill' Amgen's romosozumab development, says Canaccord
Canaccord analyst John Newman said Amgen (AMGN) and partner UCB's report of a higher rate of cardiovascular Serious Adverse Events for romosozumab in the Phase 3 ARCH study in osteoporosis suggests a much lower chance of FDA approval for the drug and may "kill" romosozumab's development. He notes that Merck's (MRK) cathepsin-K inhibitor was previously discontinued due to increased risk of atrial fibrillation and stroke. In addition to the safety signals, Newman points out that romosozumab was worse than Radius' (RDUS) Tymlos for non-vertebral fracture and for vertebral fracture, suggesting Radius' drug also has much better efficacy, said the analyst, who keeps a Buy rating and $85 price target on Radius Health shares, which are up $4.47, or 12.8%, to $39.40 in pre-market trading.
12/06/17
SBSH
12/06/17
INITIATION
Target $30
SBSH
Neutral
Radius Health initiated with a Neutral at Citi
Citi analyst Robyn Karnauskas started Radius Health with a Neutral rating and $30 price target. The analyst believes the Tymlos launch will be the key story for 2018 and prefers to wait on the sidelines until the company's cancer program comes to the forefront.

TODAY'S FREE FLY STORIES

BOX

Box

$20.47

-0.19 (-0.92%)

13:14
04/23/18
04/23
13:14
04/23/18
13:14
Hot Stocks
Breaking Hot Stocks news story on Box »

Box jumps 8% as Chamath…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$14.28

0.025 (0.18%)

13:14
04/23/18
04/23
13:14
04/23/18
13:14
Periodicals
Breaking Periodicals news story on Deutsche Bank »

Deutsche Bank weighs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

BPMP

BP Midstream

$18.84

0.55 (3.01%)

, BP

BP

$43.65

0.145 (0.33%)

13:13
04/23/18
04/23
13:13
04/23/18
13:13
Periodicals
BP Midstream holders may sell 10M more units starting Tuesday, Bloomberg says »

Large BP Midstream…

BPMP

BP Midstream

$18.84

0.55 (3.01%)

BP

BP

$43.65

0.145 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 22

    May

RYCEY

Rolls-Royce

13:10
04/23/18
04/23
13:10
04/23/18
13:10
Periodicals
Rolls-Royce weighs China JV for new wide-body aircraft, Bloomberg says »

Rolls-Royce is in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBT

BB&T

$53.38

0.66 (1.25%)

13:10
04/23/18
04/23
13:10
04/23/18
13:10
Options
Bullish option play opened in BB&T »

Bullish option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

DHI

D.R. Horton

$43.36

0.34 (0.79%)

13:00
04/23/18
04/23
13:00
04/23/18
13:00
Options
DR Horton draws far upside call writing ahead of earnings »

DR Horton draws far…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

FB

Facebook

$167.80

1.51 (0.91%)

12:58
04/23/18
04/23
12:58
04/23/18
12:58
Hot Stocks
DoubleLine's Gundlach says go short Facebook »

Jeffrey Gundlach, CEO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 25

    Apr

XOP

SPDR Oil Exploration and Production Fund

$38.82

-0.06 (-0.15%)

12:58
04/23/18
04/23
12:58
04/23/18
12:58
Hot Stocks
DoubleLine's Gundlach says go long SPDR Oil Exploration and Production Fund »

Jeffrey Gundlach, CEO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APDN

Applied DNA Sciences

12:56
04/23/18
04/23
12:56
04/23/18
12:56
Initiation
Applied DNA Sciences initiated  »

Applied DNA Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

FB

Facebook

$167.77

1.48 (0.89%)

12:55
04/23/18
04/23
12:55
04/23/18
12:55
Hot Stocks
DoubleLine's Gundlach calls apology by Facebook's Zuckerberg 'disingenuous' »

Jeffrey Gundlach, CEO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 25

    Apr

WPG

Washington Prime

12:50
04/23/18
04/23
12:50
04/23/18
12:50
Options
Washington Prime with notable put buying ahead of earnings »

Washington Prime with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

AAPL

Apple

$165.70

-0.01 (-0.01%)

12:48
04/23/18
04/23
12:48
04/23/18
12:48
Hot Stocks
CIRP: iPhone X demand slows as iPhone 8, 8 Plus mix climbs in March quarter »

Consumer Intelligence…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

OAS

Oasis Petroleum

$10.16

0.01 (0.10%)

12:45
04/23/18
04/23
12:45
04/23/18
12:45
Options
Oasis Petroleum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

ASND

Ascendis Pharma

$63.01

-0.82 (-1.28%)

12:45
04/23/18
04/23
12:45
04/23/18
12:45
Conference/Events
Ascendis Pharma has a conference call hosted by JPMorgan »

JPMorgan Analyst Fye will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 08

    May

  • 10

    May

CNSL

Consolidated Communications

$10.94

-0.04 (-0.36%)

12:41
04/23/18
04/23
12:41
04/23/18
12:41
Hot Stocks
Consolidated Communications launches DDoS mitigation solution »

Consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$68.72

0.31 (0.45%)

, LLY

Eli Lilly

$79.47

0.38 (0.48%)

12:36
04/23/18
04/23
12:36
04/23/18
12:36
Recommendations
Incyte, Eli Lilly analyst commentary  »

Incyte AdCom meeting…

INCY

Incyte

$68.72

0.31 (0.45%)

LLY

Eli Lilly

$79.47

0.38 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 01

    May

  • 07

    May

  • 21

    May

  • 07

    Jun

  • 07

    Jun

  • 12

    Jun

GRUB

GrubHub

$103.01

1.32 (1.30%)

12:35
04/23/18
04/23
12:35
04/23/18
12:35
Hot Stocks
Half Sky's Ran says GrubHub has 'significant room for growth' »

Says young people are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 29

    May

  • 12

    Jun

GRUB

GrubHub

$103.59

1.9 (1.87%)

12:30
04/23/18
04/23
12:30
04/23/18
12:30
Hot Stocks
Half Sky's Ran says GrubHub is "attractive investment idea" »

Li Ran, CIO, Half Sky…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 29

    May

  • 12

    Jun

LITE

Lumentum

$57.25

-1.65 (-2.80%)

12:27
04/23/18
04/23
12:27
04/23/18
12:27
Hot Stocks
Lumentum falls to session lows, down 5% »

Shares of Lumentum have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 29

    May

DHI

D.R. Horton

$43.22

0.2 (0.46%)

12:26
04/23/18
04/23
12:26
04/23/18
12:26
Hot Stocks
Long Pond's Khoury sees D.R. Horton at $71.50 per share »

Says incredibly strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

12:25
04/23/18
04/23
12:25
04/23/18
12:25
General news
NABE Business Conditions Survey showed strong sales expectations »

NABE Business Conditions…

12:25
04/23/18
04/23
12:25
04/23/18
12:25
Conference/Events
Leerink healthcare analysts to hold an analyst/industry conference call »

Analysts discuss dental…

PRTA

Prothena

$11.54

-25.35 (-68.72%)

, RHHBY

Roche

12:23
04/23/18
04/23
12:23
04/23/18
12:23
Recommendations
Prothena, Roche analyst commentary  »

Prothena price target…

PRTA

Prothena

$11.54

-25.35 (-68.72%)

RHHBY

Roche

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 27

    Apr

  • 27

    Apr

  • 21

    May

  • 30

    May

VZ

Verizon

$48.36

0.44 (0.92%)

, T

AT&T

$34.76

0.09 (0.26%)

12:22
04/23/18
04/23
12:22
04/23/18
12:22
Earnings
On The Fly: What to watch in telecom sector earnings reports »

Verizon (VZ) is scheduled…

VZ

Verizon

$48.36

0.44 (0.92%)

T

AT&T

$34.76

0.09 (0.26%)

S

Sprint

$5.91

-0.085 (-1.42%)

TMUS

T-Mobile

$62.59

-0.51 (-0.81%)

TWX

Time Warner

$96.13

-0.1 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 09

    May

AMZN

Amazon.com

$1,535.44

8.05 (0.53%)

, MGM

MGM Resorts

$36.31

0.88 (2.48%)

12:21
04/23/18
04/23
12:21
04/23/18
12:21
Periodicals
'Fortnite' stream in Las Vegas peaked at 667,000 viewers on Twitch, ESPN says »

A high-profile…

AMZN

Amazon.com

$1,535.44

8.05 (0.53%)

MGM

MGM Resorts

$36.31

0.88 (2.48%)

TCEHY

Tencent

DIS

Disney

$100.22

-0.02 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 08

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.